Nature Reviews Neurology

Papers
(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Lymphatic propagation of α-synuclein480
Microglia, spreaders of Aβ seeds422
Transmembrane protein interacts with α-synuclein to confer risk of PD285
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma280
Ventricular enlargement caused by aducanumab265
Getting specific: targeting Fc receptors in myasthenia gravis253
Neural cell state shifts and fate loss in ageing and age-related diseases232
Brain stimulation aids walking after spinal injury232
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications218
Refining oxytocin therapy for autism: context is key199
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms199
Global synergistic actions to improve brain health for human development197
NODDI reveals brain microstructural changes in multiple sclerosis195
Disease-specific modifications of tau protein188
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking183
Continuous levodopa production by an artificial enzyme183
The impact of rare genetic variants on Alzheimer disease171
Spinal muscular atrophy treatment in utero164
Nir Giladi (1955–2024)159
Study reveals new ALS risk genes147
Mitochondrial DNA instability in Huntington disease147
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause133
TREM2 mediates phagocytosis in glioblastoma133
Imperatives and co-benefits of research into climate change and neurological disease132
Microglia subset associated with high-grade glioma123
The Digitized Memory Clinic122
SEQUINS — a new initiative to address disparities in neurology120
The role of the gut microbiota in multiple sclerosis117
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders115
Ultrasound lets gene therapy into the brain113
Brain volume is associated with cognition in MS105
Role for endogenous retrovirus in FTD103
Menopause influences tau pathology101
Amyloid plaques: hotspots for microglial turnover99
Neurological care for LGBT+ people98
Psychosis-causing lesions mapped to a hippocampal circuit96
The challenges of anti-tau therapeutics in Alzheimer disease93
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice89
Implications of AD plasma and PET biomarker discordance89
Neuroinflammation predicts cognitive decline in FTD89
MRI-based deep learning for TLE diagnosis89
Diversity, equity and inclusion in neurology88
Brain imaging illuminates cognitive impairment in multiple sclerosis84
APOE ε4 influences Parkinson disease progression84
Author Correction: Viral pathogens increase risk of neurodegenerative disease79
Parkinson disease pathology can originate in the kidney77
First trials test targeting of α-synuclein for Parkinson disease77
Management of freezing of gait — mechanism-based practical recommendations76
Precision neuroimmunology in multiple sclerosis — the horizon is near76
Gene therapy for seizures in focal cortical dysplasia73
α-Synuclein pathology as a target in neurodegenerative diseases71
Evidence for altered astrocyte function in Duchenne muscular dystrophy71
Blood GFAP as an emerging biomarker in brain and spinal cord disorders71
New IDEAS about amyloid, race and dementia disparities70
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus70
Food is brain medicine — relevance and translation to neurology65
Neurosteroids alleviate seizures in rats64
Glymphatic dysfunction in PD clinical progression61
Thalamic inflammation — a therapeutic target for brain injury?61
A new biological classification for Parkinson disease60
Exosomal microRNA is promising biomarker in PD60
Ultrasound ablation treatment for PD58
Addressing disparities in neurology by building the workforce in LMICs58
Coeliac disease as a model for understanding multiple sclerosis58
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease55
Post-COVID dysautonomias: what we know and (mainly) what we don’t know55
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus54
Is Alzheimer disease a disease?53
Spinal cord stimulation for the treatment of chronic pain52
Synaptic degeneration in Alzheimer disease52
The global and regional burden of diabetic peripheral neuropathy52
The role of glial cells in multiple sclerosis disease progression52
From the prodromal stage of multiple sclerosis to disease prevention51
Apparent changes in the epidemiology and severity of multiple sclerosis45
Hypothalamus loses control in migraine44
Oligomeric tau could spread through synapses in AD44
X-chromosome variants and PD in Latin America43
Hypothyroidism is associated with dementia risk43
Neurofilament light chain induces neuroinflammation42
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence42
Cognitive impairment and World Trade Centre-related exposures42
Peripheral nervous system immune-related adverse events due to checkpoint inhibition42
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis41
The inter-relationship between delirium and dementia: the importance of delirium prevention41
Global epidemiology of migraine and its implications for public health and health policy40
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases39
CAR T cells offer hope in glioblastoma39
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management38
Safety and efficacy of COVID-19 vaccines in people with neurological disorders38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis38
Dual function of biomolecular condensates37
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction36
Moving towards meaningful patient and public engagement36
Risk locus for paediatric astrocytoma identified35
α-Synuclein seeds in amyotrophic lateral sclerosis34
Change in stroke outcomes over 20 years34
New developments in guidelines for brain death/death by neurological criteria33
Reactive astrocyte biomarkers mirror Alzheimer disease pathology33
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci33
Prognostic plasma biomarkers for spinal cord injury33
Huntington disease-like 2: insight into neurodegeneration from an African disease32
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology32
Facioscapulohumeral muscular dystrophy: the road to targeted therapies32
Positron emission tomography in multiple sclerosis — straight to the target32
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders30
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease30
Inflammasomes in neurological disorders — mechanisms and therapeutic potential28
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease28
Origins and immunopathogenesis of autoimmune central nervous system disorders27
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease26
Twin study probes non-heritable immune aspects of multiple sclerosis25
Deep learning distinguishes tauopathies25
High rate of epilepsy in young individuals who died with COVID-1924
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response24
Neurogenesis altered in multiple neurodegenerative diseases24
Serum NfL as an MS biomarker23
Charting brain development across the human lifespan23
Genome-wide analysis furthers decoding of Alzheimer disease genetics22
Does antiherpetic antiviral therapy reduce the risk of dementia?21
The murky waters of sex differences in post-stroke cognitive impairment21
Aberrant protein networks in Alzheimer disease20
AI and protein structure and function in neurological disease: relevance to disease management20
ALS pathogenesis linked to actin barrier collapse20
John Q. Trojanowski20
Author Correction: The complex aetiology of cerebral palsy19
BCAS1+ oligodendrocytes aid remyelination in MS19
Alzheimer disease in African American individuals: increased incidence or not enough data?18
Pharmacological rehabilitation for stroke17
AI aces diagnosis of chronic ataxias17
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era17
Pathogenetic mechanisms and treatment targets in cerebral malaria16
Molecular biomarkers for vascular cognitive impairment and dementia16
Neuroprognostication: a conceptual framework16
Addressing disparities in the global epidemiology of stroke16
Clocking the age of Parkinson disease onset14
Effects of diet on MS onset and course14
Nusinersen treatment response markers13
Altered muscle cholesterol transport in ALS13
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis13
Alzheimer disease seen through the lens of sex and gender13
Predictive tools in psychosis: what is ‘good enough’?13
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies12
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms11
Sex and gender in neurodevelopmental conditions11
Mechanistic insights into the interaction between epilepsy and sleep11
Nanoprobe for blood–brain barrier changes11
0.052968978881836